ERBB2 and breast carcinoma: HER4, another member of the ErbB family, also reportedly impacts HER2-positive cancer cell survival after cells become resistant to trastuzumab, and nuclear localization of HER2 indicateed a poor prognosis in breast cancer [22, 23].